[
    {
        "utterance": "Noah Palm: and picking, you know, like so for Parkinson's disease um, uh you may use something like constipation as a sign of potential prodromal Parkinsons. Then you design a large cohort of people that fit that characteristic, collect as early on as when they show that particular set of biomarkers. ",
        "annotations": {
            "provide_supporting_evidence": "Noah is providing an example (constipation as a sign of prodromal Parkinson's) to support his idea of picking specific biomarkers for early disease detection.",
            "expand_on_existing_idea": "Noah is building on his previous point about picking biomarkers by explaining how this could be applied to Parkinson's disease.",
            "explain_or_define_term_or_concept": "Noah is explaining the concept of using a specific symptom (constipation) as a potential early indicator of Parkinson's disease."
        }
    },
    {
        "utterance": "Noah Palm: um, uh and um and you work your way back from there. See basically what's the earliest you can get uh uh yeah, get a signal ",
        "annotations": {
            "expand on existing idea": "Noah is further elaborating on the previously mentioned idea of designing a cohort and collecting data by explaining how to work backward to find the earliest detectable signal.",
            "explain or define term or concept": "Noah is explaining the concept of working backward from a later stage of Parkinson's disease to identify the earliest signals."
        }
    },
    {
        "utterance": "Noah Palm: um uh from those populations. Yeah, again, I I I don't work really in this biomarker field at all, but it does feel like there's got to be some way of working backwards and obviously having just really big cohorts of all the data at from birth on is one way to do it. That's what ",
        "annotations": {
            "provide supporting evidence": "Noah Palm supports the idea of working backwards from biomarkers by suggesting the use of large cohorts with data from birth.",
            "present new idea": "Noah Palm introduces the idea of using large cohorts with data from birth as a way to find early signals of diseases like Parkinson's.",
            "explain or define term or concept": "Noah Palm explains the concept of working backwards by describing how it applies to finding early biomarkers."
        }
    },
    {
        "utterance": "Noah Palm: you know, they're better at doing that in Europe, Scandinavia, etc than we are here. I think from from what I've seen. Um, but in lieu of that, um, you know, maybe trying to work your way backwards with guessing at people who are eventually going to develop the disease based on marker X and then developing a slightly better guess that allows you to work your way a little bit backwards in years um iteratively. ",
        "annotations": {
            "expand on existing idea": "Noah is elaborating on the previously discussed idea of working backwards from potential indicators of Parkinson's disease by suggesting an iterative process of refining the selection criteria based on marker X.",
            "provide supporting evidence": "Noah supports his suggestion by mentioning the better data collection practices in Europe and Scandinavia, implying that working backwards is a viable approach.",
            "present new idea": "Noah introduces the new idea of an iterative process of refining the selection criteria based on marker X, starting with an initial guess and gradually improving it over time."
        }
    },
    {
        "utterance": "Carolina Tropini: I think that's a really good point about the the timing component and the I think for the microbiome field, one of the challenges is that the effects happen after such a long period of time. And if we're looking at even neurodegenerative diseases, it's I think that it's very restrictive to only look at the aging population for this because likely the effects of the microbiota will be happening over decades. And so that presents a challenge, but also an opportunity to set up systems that will fund research that can really span an entire lifetime. ",
        "annotations": {
            "acknowledge contribution": "Carolina acknowledges Noah's point about the timing component being important.",
            "provide supporting evidence": "Carolina supports her claim about the challenge of microbiome research by stating that the effects happen over a long period, especially in neurodegenerative diseases, which makes it restrictive to only look at the aging population.",
            "present new idea": "Carolina presents the idea of setting up systems to fund research that spans an entire lifetime to address the challenge of long-term effects in microbiome research, particularly for neurodegenerative diseases."
        }
    },
    {
        "utterance": "Carolina Tropini: and and also here, you know, the study design becomes really important, of course, because you you want to be following people for a really long time so that some of these microbiota effects can become evident. ",
        "annotations": {
            "expand on existing idea": "Carolina expanded on the previously discussed challenge of early diagnosis by emphasizing the importance of study design for long-term microbiota effects.",
            "provide supporting evidence": "Carolina supports the need for long-term studies by explaining that microbiota effects on neurodegenerative diseases can take decades to manifest.",
            "explain or define term or concept": "Carolina explains that the importance of study design lies in the need to follow individuals over a long period to observe microbiota effects."
        }
    },
    {
        "utterance": "Kaixiong Ye: Yeah, and I think that kind of data set follow a large number of individuals for for their lifetime, keep check of electronic health record or the biomarker. That's my dream data set. ",
        "annotations": {
            "expand on existing idea": "Calvin expands on Carolina and Noah's prior discussion of the challenges of studying long-term effects by emphasizing the value of a dataset that tracks individuals over their lifetime and includes health records and biomarkers.",
            "express enthusiasm": "Calvin describing the dataset as his \"dream dataset\" indicates excitement and a strong positive attitude towards this type of data collection."
        }
    },
    {
        "utterance": "Kaixiong Ye: And right now we have look at those data set not the same, but we have similar data set UK Bank 50,000 individuals, electronic health record a lot of data, but they do not have microbiome. So so ideally we start a cohort, follow them for a long time. ",
        "annotations": {
            "provide_supporting_evidence": "Calvin mentions the UK Bank dataset with 50,000 individuals and electronic health records as a similar dataset to support the need for a longitudinal study with microbiome data.",
            "present_new_idea": "Calvin proposes the idea of starting a cohort and following them for a long time to collect microbiome data.",
            "expand_on_existing_idea": "Building on the previous discussion about the limitations of existing datasets, Calvin suggests creating a new dataset that includes microbiome data and follows individuals over a long period."
        }
    },
    {
        "utterance": "Kaixiong Ye: And there there's one possibility to help us narrow down the the the participant. We can use genetic data to predict who has a higher risk for specific uh neurodegenerative disease and that can help us focus on people that are predicted to have higher risk. Can reduce the sample size a little bit? I just an idea. ",
        "annotations": {
            "present new idea": "Calvin suggests using genetic data to predict individuals at higher risk of neurodegenerative diseases to narrow down the participant pool for longitudinal studies.",
            "expand on existing idea": "Calvin builds upon the previously discussed need for large, long-term datasets by suggesting a method to refine participant selection and reduce the necessary sample size.",
            "provide supporting evidence": "None",
            "explain or define term or concept": "None",
            "ask clarifying question": "None",
            "propose decision": "Calvin proposes using genetic data to pre-select participants for the study.",
            "confirm decision": "None",
            "express alternative decision": "None",
            "express agreement": "None",
            "assign task": "None",
            "offer constructive criticism": "None",
            "reject idea": "None",
            "resolve conflict": "None",
            "express frustration": "None",
            "acknowledge contribution": "None",
            "encourage participation": "None",
            "express enthusiasm": "None",
            "express humor": "None"
        }
    },
    {
        "utterance": "Noah Palm: I would almost argue though the opposite, which is that really what you want to get the strongest signal are the people who have no genetic predisposition. But uh regardless of that, end up actually getting Alzheimer's, which would suggest that they have a stronger actually environmental or microbial component. And the people who are have genetically predisposed would actually have a weaker signal for non-genetic biomarkers. ",
        "annotations": {
            "present new idea": "Noah Palm presents a new idea about focusing on individuals without genetic predisposition to Alzheimer's to get a stronger signal for environmental or microbial components.",
            "expand on existing idea": "Noah Palm expands on Kaixiong Ye's idea of narrowing down participants by suggesting the opposite approach.",
            "provide supporting evidence": "Noah Palm supports his idea by reasoning that those without genetic predisposition would have a stronger environmental/microbial component if they develop Alzheimer's.",
            "offer constructive criticism": "Noah Palm offers constructive criticism of Kaixiong Ye's idea of using genetic data to narrow down participants by suggesting an alternative approach."
        }
    },
    {
        "utterance": "Noah Palm: because they would need less. Yeah. ",
        "annotations": {
            "provide_supporting_evidence": "Noah Palm supports his prior argument about individuals with genetic predisposition having weaker signals for non-genetic biomarkers by stating they would need less environmental influence to develop the disease."
        }
    },
    {
        "utterance": "Heather Bean: But there might be a really strong signal in the people who are genetically predisposed but do not develop the disease. Yeah. You mean for a protective biomarker? Yeah, and and maybe the protective biomarker doesn't, you know, really work, um, for predicting disease, but that might kind of, um, split the difference on being able to narrow down a target population and then still be able to find a strong signal. ",
        "annotations": {
            "present new idea": "Heather proposes that there might be a strong signal in individuals genetically predisposed to a disease but who do not develop it, suggesting a protective biomarker.",
            "expand on existing idea": "Heather builds upon the previous discussion of genetic predisposition and biomarkers by suggesting that protective biomarkers could help narrow down the target population and find a strong signal.",
            "provide supporting evidence": "Heather supports her idea by explaining that while protective biomarkers may not predict disease, they could help identify a target population with a strong signal.",
            "explain or define term or concept": "Heather clarifies the concept of a \"protective biomarker\" as one found in individuals genetically predisposed to a disease but who do not develop it.",
            "ask clarifying question": "Heather asks \"You mean for a protective biomarker?\" to confirm her understanding of the previous speaker's intent."
        }
    },
    {
        "utterance": "Kaixiong Ye: The the key here is that you need to think about at the end, how many of the subject will develop the outcome so that you have enough sample size for you to test. Although we start with a higher risk cohort, not all of them will develop the outcome. It just a higher risk. ",
        "annotations": {
            "expand on existing idea": "Calvin is building on the previous discussion of cohort selection by emphasizing the importance of considering the final sample size of those who develop the outcome.",
            "provide supporting evidence": "Calvin supports his point by explaining that even in a high-risk cohort, not everyone will develop the outcome, thus impacting the statistical power of the study.",
            "explain or define term or concept": "Calvin clarifies the concept of \"higher risk\" by explaining that it doesn't guarantee the development of the outcome but increases the probability."
        }
    },
    {
        "utterance": "Kaixiong Ye: And then by looking them like just help us reduce the sample size at the beginning, but still able to achieve enough sample size at the end. ",
        "annotations": {
            "expand on existing idea": "Calvin is building on his prior idea about using genetic data to pre-select participants by adding the detail that this approach helps reduce initial sample size while ensuring sufficient outcome events.",
            "explain or define term or concept": "Calvin explains the concept of using genetic predisposition not as a definitive outcome predictor but as a way to enrich the sample with higher-risk individuals, clarifying his earlier point."
        }
    },
    {
        "utterance": "George Weinstock: Let me just also mention though, let's not totally focus on neurodegenerative diseases, right? I mean, there's autism for little kids, there's addiction, there's um schizophrenia, there's there's all kinds of other mental health conditions that are not necessarily things that you have to wait uh the whole lifetime for. ",
        "annotations": {
            "present new idea": "George Weinstock suggests broadening the research focus to include other mental health conditions beyond neurodegenerative diseases, such as autism, addiction, and schizophrenia, which may have shorter timeframes for observing effects.",
            "provide supporting evidence": "He supports this by pointing out that these conditions do not require waiting a lifetime to study, unlike neurodegenerative diseases.",
            "offer constructive criticism": "George Weinstock gently cautions against solely focusing on neurodegenerative diseases, implying that a broader perspective might be more fruitful."
        }
    },
    {
        "utterance": "Heather Bean: Depression. ",
        "annotations": {
            "present new idea": "Heather is proposing \"Depression\" as another mental health condition to consider, in addition to those already mentioned by George Weinstock.",
            "expand on existing idea": "Heather adds \"Depression\" to the list of mental health conditions suggested by George, expanding on his idea of exploring conditions beyond neurodegenerative diseases."
        }
    },
    {
        "utterance": "George Weinstock: Depression, right? ",
        "annotations": {
            "confirm decision": "George confirms Heather's suggestion of depression as another mental health condition that could be studied, as indicated by the word \"right?\""
        }
    }
]